In Brief: 01 April 2010 – ACR
April 1, 2010
Acrux Limited (ACR) said the US rights to the testosterone spray for women Luramist would return to Acrux subsidiary FemPharm after the US licensee for the product Vivus Inc. provided notice to terminate the license agreement. Acrux said as a result FemPharm would now own and control worldwide rights to the product. The developments followed the failing of Vivus to start the Luramist Phase 3 trial by the outside date of 1 April 2010 that was set by the independent arbitration panel. The company said it believes the product has the potential to generate very strong commercial returns for Acrux, being potentially the best-in-class product in a billion dollar market.
Leave a Reply